
Key Financial & Performance Highlights

(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became a subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

FY1516 vis-a-vis FY1415:
- Income from operations grew 20.6% to Rs. 13,678 cr, up from Rs. 11,345 cr
- EBITDA increased 15.7% to Rs. 2,501 cr, up from Rs. 2,162 cr
- Profit after tax increased 27.5% to Rs. 1,506 cr, up from Rs. 1,181 cr

Q4 FY1516 vis-a-vis Q4 FY1415:
- Income from operations grew 5.6% to Rs. 3,267 cr, up from Rs. 3,093 cr
- EBITDA declined 56.9% to Rs. 219 cr, down from Rs. 508 cr
- Profit after tax declined 68.9% to Rs. 81 cr, down from Rs. 260 cr

Summary Performance Review for Full Year FY1516

Domestic business:
- Domestic business contributed ~40% of overall Company sales
- Ranked #3 in the Indian Pharmaceutical Market, with a market share of ~5.3%
- Domestic sales grew 5.9% to Rs. 5,111 cr during FY1516, up from Rs. 4,825 cr during FY1415
- Domestic sales grew 15.9% to Rs. 1,258 cr during Q4 FY1516, up from Rs. 1,086 cr during Q4 FY1415
- Growth momentum in Respiratory, Anti-infectives, Urology and Gastro Intestinal therapies

Exports business:
- Exports of formulations increased 38.0% to Rs. 7,483 cr during FY1516, from Rs. 5,422 cr during FY1415
- Exports of formulations increased 3.2% to Rs. 1,744 cr during Q4 FY1516, from Rs. 1,690 cr during Q4 FY1415
- Strong growth in North America, South Africa and key front-end emerging markets
- Completed acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc.
- Exports of APIs increased 22.5% to Rs. 778 cr during FY1516, from Rs. 636 cr during FY1415
- Exports of APIs remained flat at Rs. 204 cr during Q4 FY1516, compared to Rs. 205 cr during Q4 FY1415
About Cipla Limited:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:

**Investor Relations**
Anant Atal
Contact No.: 022 – 24826450
E-Mail: anant.atal@cipla.com

**Corporate Communications**
Pallavi Golar
Contact No.: +91 9833641788
E Mail: pallavi.golar@cipla.com